What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Side effects
Page 13 of 21 of this archive, newest first.
Holidays, surgery, sickness: interruption in practice
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
When to stop escalating and when to stop entirely
We set out the questions that distinguish a symptom to manage from a dose to change.
What the new Denmark guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Canada pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Switzerland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Poland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Antiemetics, laxatives and the thin literature underneath them
Constipation is the most tractable of the effects and the most consistently under-managed.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Reflux, early satiety, and the volume the stomach will accept
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Mexico guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Canada pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.